Examining the combined benefits of photobiomodulation and apigenin for the treatment of asthenozoospermia: An innovative therapeutic strategy.

Individuals suffering from asthenospermia, an infertility disorder, have reduced sperm motility. This study's goal was to identify the impacts of diverse photobiomodulation procedures on the motility of sperm in vitro in patients with asthenospermia, either in isolation or in combination with Apigenin. At 633 nm and 808 nm, the lasers are used with multiple dose values (0.6, 1.2, and 2.4) J/cm and altering Apigenin concentrations (5, 10, 25, and 50 μM). All of the photobiomodulation procedures were assessed. Assessing factors were the DNA fragmentation index, sperm viability, as well as progressive sperm motility. The progressive sperm motility results for 633 nm and 808 nm show a significant increase over 633 nm + 808 nm after 60 min after irradiation. Sperm motility increased more quickly under the 808 nm procedure than under the other procedures (p < 0.02). The observation of progressive sperm motility indicated that a 10 μM concentration of Apigenin created higher results than other concentrations (p < 0.01). Apigenin with 808 nm at 1.2 J/cm resulted in better sperm motility (p < 0.01) and decreased DNA fragmentation index. There was a notable increase (p < 0.05) in the DNA fragmentation index with the 633 nm + 808 nm procedure. At a 10 μM concentration of Apigenin, the DNA fragmentation index was lower than at a 50 μM concentration (p < 0.02). Neither Apigenin nor photobiomodulation significantly decreased sperm viability. The study suggests that asthenozoospermia patients may benefit from apigenin utilized alongside photobiomodulation, while further investigation is required.